CNSP CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas.

$1.11
As of 11/30/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1997
Outstanding shares:  27,920,967
Average volume:  342,957
Market cap:   $32,109,112
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    18978H102
ISIN:        US18978H1023
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.35
PS ratio:   0.00
Return on equity:   -156.55%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy